Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464–77. https://doi.org/10.1001/jama.2022.0003.

Article  CAS  PubMed  Google Scholar 

Global Cancer Observatory: Data visualization tools for exploring the global cancer burden in 2022. https://gco.iarc.who.int/today (2024). Accessed Nov 28 2024.

Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37. https://doi.org/10.1007/s40265-017-0841-y.

Article  CAS  PubMed  Google Scholar 

Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–22. https://doi.org/10.1016/j.annonc.2020.11.014.

Article  CAS  PubMed  Google Scholar 

Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52–61. https://doi.org/10.1093/annonc/mdx096.

de Moraes Hungria VT, Peña C, Gómez-Almaguer D, Martínez-Cordero H, Schütz NP, Blunk V. Multiple myeloma in Latin America: a systematic review. eJHaem. 2024;5(4):867–78. https://doi.org/10.1002/jha2.905.

Article  PubMed  PubMed Central  Google Scholar 

Argentine Agency of the Registry of the National Administration of Medicines FaMTA. INFORMACIÓN PARA EL PACIENTE—Darzalex® (Daratumumab) 100 mg/5 ml; 400 mg/20 ml, Buenos Aires; 2022.

Argentine Agency of the Registry of the National Administration of Medicines FaMTA. Revlimid®5/10/15/25 mg Product Information—Argentina. Buenos Aires; 2023.

Agência Nacional de Vigilância Sanitária—Anvisa: Novo tratamento de câncer é aprovado pela Anvisa (2022). https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2018/novo-tratamento-de-cancer-e-aprovado-pela-anvisa. Accessed May 2 2025.

Kumar S, Baizer L, Callander NS, Giralt SA, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee. Blood Cancer J. 2022;12(6):98. https://doi.org/10.1038/s41408-022-00695-5.

Article  PubMed  PubMed Central  Google Scholar 

Bhatt P, Kloock C, Comenzo R. Relapsed/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322–47. https://doi.org/10.3390/curroncol30020179.

Article  PubMed  PubMed Central  Google Scholar 

Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC. Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024;21(8):590–609. https://doi.org/10.1038/s41571-024-00913-y.

Article  CAS  PubMed  Google Scholar 

Yang WC, Lin SF. Mechanisms of drug resistance in relapse and refractory multiple myeloma. BioMed Res Int. 2015;2015:341430. https://doi.org/10.1155/2015/341430.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993–6002. https://doi.org/10.1182/bloodadvances.2024014139.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–24. https://doi.org/10.1002/ajh.27422.

Article  PubMed  PubMed Central  Google Scholar 

Hungria V. MM therapy in resource-constrained including maintenance. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 1):S100–1. https://doi.org/10.1016/S2152-2650(24)00363-X.

Article  Google Scholar 

Hartley-Brown MA, Weisel K, Bitetti J, Carter JA, McNamara S, Purser M, et al. Multiple myeloma refractory to lenalidomide: a systematic literature review of trials and real-world evidence. Br J Haematol. 2024;205(3):780–97.

Article  CAS  PubMed  Google Scholar 

Kastritis E, Theodorakakou F, Ntanasis-Stathopoulos I, Spiliopoulou V, Solia E, Malandrakis P, et al. Management and outcomes of anti-CD38 refractory myeloma patients: the impact of retreatment and of subsequent therapies. Blood. 2022;140(Suppl 1):7324–5. https://doi.org/10.1182/blood-2022-165792.

Article  Google Scholar 

McNamara SC J, Pandey A, Bitetti J, Boytsov N, Purser M, Iheanacho I. CO75 clinical outcomes associated with anti-CD38 retreatment in relapsed/refractory multiple myeloma: a review of the literature. Value Health. 2024;27(Suppl 6):S31. https://doi.org/10.1016/j.jval.2024.03.163.

Article  Google Scholar 

da Silva Ferreira K, Rafael Maciel JF, de Souza Rego Pinto Carvalho DP, Campos de Azevedo I, Fortes Vitor A, Ferreira Júnior MA. Caracterización clínica y supervivencia de pacientes con múltiple mieloma en un estado del noreste Brasil. Rev Cuba Hematol Inmunol Hemoter. 2017;33(2):1–9.

Peña C, Riva E, Schutz N, Tarín-Arzaga L, Martínez-Cordero H, Bove V, et al. Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. Leuk Lymphoma. 2020;61(13):3112–9. https://doi.org/10.1080/10428194.2020.1804558.

Article  PubMed  Google Scholar 

de Moraes Hungria VT, Martínez-Baños DM, Peñafiel CR, Miguel CE, Vela-Ojeda J, Remaggi G, et al. Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato-Oncology (HOLA) observational study, 2008–2016. Br J Haematol. 2020;188(3):383–93. https://doi.org/10.1111/bjh.16124.

Article  PubMed  Google Scholar 

The Economist Group: Multiple myeloma in Latin America: supporting early and equitable access to care to improve patient outcomes (2023). https://impact.economist.com/perspectives/sites/default/files/ei_janssen_mm_latam_final.pdf. Accessed Nov 24 2024.

Ribbands A, Boytsov N, Bailey A, Gorsh B, Luke E, Lambert A. Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA. Future Oncol. 2023;19(22):1549–62.

Article  CAS  PubMed  Google Scholar 

Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, et al. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Front Med. 2023;10:1271657. https://doi.org/10.3389/fmed.2023.1271657.

Article  Google Scholar 

Choon-Quinones M, Zelei T, Barnett M, Keown P, Durie B, Kalo Z, et al. Exploring the true cost of multiple myeloma. Am J Hematol. 2020;95(Suppl 1):S8–9. https://doi.org/10.1002/ajh.26005.

Article  Google Scholar 

Martínez-Lopez J, Bailey A, Lambert A, Luke E, Ribbands A, Erler-Yates N, et al. Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe. Future Oncol. 2023;19(31):2103–21. https://doi.org/10.2217/fon-2023-0021.

Article  CAS  PubMed  Google Scholar 

Steinmetz TH, Singh M, Lebioda A, Fink L, Schoehl M, Rieth A, et al. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. J Med Econ. 2021;24(1):114–22. https://doi.org/10.1080/13696998.2020.1867469.

Article  PubMed  Google Scholar 

Crusoe E, Ribeiro G, Zanella K, Perobelli L, Filho JCS, Magalhaes R, et al. Multiple myeloma Brazilian register- how about the transplant eligible patients? HemaSphere. 2022;6:3449–50. https://doi.org/10.1097/01.HS9.0000852292.38263.b8.

Article  Google Scholar 

Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, et al. Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol. 2019;98(4):941–9. https://doi.org/10.1007/s00277-019-03602-4.

Article  PubMed  Google Scholar 

Mela Osorio MJ, Pavlovsky C, Pavlovsky MA. Inequalities in access to treatment in Argentina: differences in management of CLL and multiple myeloma? Semin Hematol. 2023;60(4):209–14. https://doi.org/10.1053/j.seminhematol.2023.07.001.

Article  PubMed  Google Scholar 

Peña C, Graffigna P, Russo M, Forray E, Bustamante P. Improved overall survival of transplant eligible newly diagnosed multiple myeloma patients in a Chilean public center. How did we achieve it? Hematol Transfus Cell Ther. 2024;46(4):575–6. https://doi.org/10.1016/j.htct.2024.02.024.

Article  PubMed  PubMed Central  Google Scholar 

Samaniego F, Bull L, González N, Araos D, Rojas H, Donoso J, et al. Mieloma múltiple en Chile. Uso de drogas noveles en dos centros nacionales. Rev Med Chile. 2022;150(3):331–8. https://doi.org/10.4067/s0034-98872022000300331.

Article  PubMed  Google Scholar 

Curado MP, Oliveira MM, Silva DRM, Souza DLB. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med. 2018;7(5):2101–8. https://doi.org/10.1002/cam4.1347.

Article  PubMed  PubMed Central  Google Scholar 

Guimarães Ribeiro A, Ferlay J, Piñeros M, Dias de Oliveira Latorre MDR, Tavares Guerreiro Fregnani JH, Bray F. Geographic variations in cancer incidence and mortality in the State of São Paulo, Brazil 2001–17. Cancer Epidemiol. 2023;85:102403.